Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02532140 · ClinicalTrials.gov registry record · Phase 1
Study to Evaluate the Safety, Tolerability, and Pharmacokinetics of WCK 5107 Alone and in Combination With Cefepime
A Phase 1 study of Healthy, sponsored by Wockhardt.
- Completed
- Registry status
- Phase 1
- Development phase
- 88
- Enrollment target
- 1
- Study location
NCT02532140: Completed Phase 1 study of Healthy, sponsored by Wockhardt.
NCT02532140 is a Phase 1 study of Healthy that has completed, run by Wockhardt. The registered enrollment target is 88 participants, below the 647-participant average among 1,090 other Healthy trials with a reported enrollment target (86% lower). The trial reports 1 study location across 1 state. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT02532140, a Phase 1 study of Healthy, has completed, sponsored by Wockhardt.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 88 participants
- Enrollment target
- 1
- Study location
Study Summary
• To evaluate the safety,tolerability and pharmacokinetics of single intravenous doses of WCK 5107 alone and in combination with cefepime in healthy adult human subjects.
Primary Outcome
To evaluate the safety of single intravenous doses of WCK 5107 alone and in combination with cefepime in healthy adult human subjects.
Conditions Studied
Interventions
- DRUG Placebo
- DRUG WCK 5107 250 mg to 2000 mg
- DRUG Cefepime 2000 mg
- DRUG WCK 5107 1000/2000 mg with Cefepime 2000 mg combination
Study Locations (1)
Kansas
- Quintiles - Overland Park
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 88 participants |
| Start Date | 2015-08 |
| Est. Completion | 2015-12 |
| Phase | Phase 1 |
What the finished NCT02532140 record still lists
NCT02532140 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 88 participants, a relatively small participant target, below the 647-participant average among 1,090 other Healthy trials with a reported enrollment target (86% lower).
The record links to 1 condition, with Healthy appearing as the primary indexed condition, and to 4 interventions - of which Placebo is the first listed.
NCT02532140 reports a single indexed study location in Kansas.
Frequently Asked Questions
What is clinical trial NCT02532140 about?
NCT02532140 is a clinical study titled "Study to Evaluate the Safety, Tolerability, and Pharmacokinetics of WCK 5107 Alone and in Combination With Cefepime". • To evaluate the safety,tolerability and pharmacokinetics of single intravenous doses of WCK 5107 alone and in combination with cefepime in healthy adult human subjects.
What is the current status of trial NCT02532140?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 88 participants. The study started on 2015-08. Estimated completion is 2015-12.
What conditions does trial NCT02532140 study?
This clinical trial studies the following conditions: Healthy.
What interventions are being tested in trial NCT02532140?
The interventions under investigation include: Placebo (DRUG), WCK 5107 250 mg to 2000 mg (DRUG), Cefepime 2000 mg (DRUG), WCK 5107 1000/2000 mg with Cefepime 2000 mg combination (DRUG).
Who is sponsoring clinical trial NCT02532140?
This trial is sponsored by Wockhardt, which has 27 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT02532140 being conducted?
This trial has 1 study location across Kansas. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Healthy
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT02532140's enrollment target sits among peer trials
88 259th of 1090 higher than 831 of 1,090 other Healthy trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Healthy trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
Assessment of Neuroinflammation in Central Inflammatory Disorders Using [F-18]DPA-714.
RECRUITING · Phase 1
-
A Study of LY3867070 in Healthy Participants
RECRUITING · Phase 1
-
A Study to Investigate Safety, Tolerability, Pharmacokinetics, Pharmacodynamics and Immunogenicity of AZD1613 in Healthy Participants.
RECRUITING · Phase 1
-
Evaluate the Pharmacokinetics, Safety, and Tolerability of NSHO-101 in Healthy Participants
RECRUITING · Phase 1
-
Comparison of the Short-Term Effect of Dietary Carbohydrate Restriction Versus Exogenous Ketone Supplementation on Myocardial Glucose Suppression and Timing to Achieve a State of Ketosis Using FDG PET/CT Serial Imaging
RECRUITING · Phase 1
-
A Study of V118E in Healthy Participants (V118E-003)
RECRUITING · Phase 1
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT03843463 · 88 participants · Phase 2
Escitalopram and Language Intervention for Subacute Aphasia
- NCT04066348 · 88 participants · Phase 2
TNF-α Treatment of Blast-Induced Tinnitus
- NCT04331704 · 88 participants · Phase 4
ANCHORS Alcohol & Sexual Health Study: UH3 Project
- NCT04536103 · 88 participants
Multi-Vendor Multi-Site Novel Accelerated MRI Relaxometry
Similar registry start date
- NCT05988463 · started 2027-01-01 · Phase 1
Dose-Escalation Study of Artesunate Patients With IPF
- NCT07219706 · started 2026-12-10 · NA
Dietary Fiber and Time Restricted Eating
- NCT02831335 · started 2026-12-01
Technical Development of Multi-Parametric Renocerebral MRI
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia